Description: Day One Biopharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops and commercializes targeted therapies for patients with genetically defined cancers. Its lead product candidate is DAY101, an oral brain-penetrant type II pan-rapidly accelerated fibrosarcoma kinase inhibitor that is in Phase II clinical trial for pediatric patients with relapsed/progressive low-grade glioma. The company is also developing Pimasertib, an oral small molecule inhibitor of mitogen-activated protein kinase kinases 1 and 2. Day One Biopharmaceuticals, Inc. was incorporated in 2018 and is headquartered in South San Francisco, California.
Home Page: dayonebio.com
DAWN Technical Analysis
395 Oyster Point Boulevard
South San Francisco,
CA
94080
United States
Phone:
650 484 0899
Officers
| Name | Title |
|---|---|
| Dr. Jeremy Bender M.B.A., Ph.D. | CEO, Pres & Director |
| Dr. Samuel C. Blackman M.D., Ph.D. | Co-Founder & Chief Medical Officer |
| Ms. Julie Papanek Grant M.B.A. | Co-Founder & Director |
| Mr. Charles N. York II | COO, CFO & Sec. |
| Dr. Mike Preigh Ph.D. | Chief of Technology Operations |
| Mr. Adam Dubow | Gen. Counsel |
| Ms. Jaa Roberson | Chief People Officer |
| Dr. Davy Chiodin Ph.D., Pharm.D. | Chief Devel. Officer |
Exchange: NASDAQ
Country: US
Currency: US Dollar ($)
| Forward PE: | 0 |
|---|---|
| Trailing PE: | 3.98 |
| Price-to-Book MRQ: | 4.1528 |
| Price-to-Sales TTM: | 0 |
| IPO Date: | 2021-05-27 |
| Fiscal Year End: | December |
| Full Time Employees: | 102 |